Compare
Enhertu vs. Herceptin

Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved to treat adults with cancers that have a tumor marker protein called HER2. These include breast cancer, non-small cell lung cancer (NSCLC), stomach cancer, esophageal cancer, and other solid tumors. Enhertu is a targeted cancer treatment called an antibody-drug conjugate (ADC). It's usually used when certain past treatments haven't worked well. The dose is given as an infusion through the vein, or IV, every 3 weeks. Common side effects include nausea, tiredness, and hair loss.

• Advanced or metastatic HER2-positive or HER2-low breast cancer
• Advanced or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
• Advanced or metastatic non-small cell lung cancer with HER2 mutations
• Advanced or metastatic HER2-positive stomach cancer
• Advanced or metastatic HER2-positive esophageal cancer
• Advanced or metastatic HER2-positive solid tumors

• Low white blood cell count (up to 73%)
• Nausea (72%)
• Lower hemoglobin levels (67%)
• Feeling very tired (55%)
• Lower platelet levels (48%)
• Higher liver enzyme levels (up to 46%)
• Vomiting (38%)
• Hair loss (37%)
• Constipation (32%)
• Low potassium levels (32%)
• Low appetite (31%)
• Diarrhea (30%)
• Muscle, bone, or joint pain (24%)

• Lung problems
• Low white blood cell count (neutropenia)
• Problems with heart function
• Harm to an unborn baby

Herceptin (trastuzumab) is a targeted anticancer treatment for certain HER2-positive cancers. It treats HER2-positive, early-stage, breast cancer (after breast surgery to remove the tumor) and late-stage, metastatic breast cancer (spread to other parts of the body). It can also treat HER2-positive, metastatic stomach cancer. Herceptin (trastuzumab) is most often used together with other anticancer medications, but can also be used by itself. Depending on the type of cancer, Herceptin (trastuzumab) can be injected into a vein (intravenous, IV) or under the skin (subcutaneous, SQ).

• HER2-positive, breast cancers - IV and SQ injections
• HER2-positive, metastatic stomach cancer - IV injection only

• Body and joint pain (up to 47%)
• Weakness (up to 42%)
• Fever (up to 36%)
• Nausea (to up 33%)
• Chills (up to 32%)
• Headache (up to 26%)
• Cough (up to 26%)
• Diarrhea (up to 25%)
• Vomiting (up to 23%)
• Infection (up to 20%)

^{*Side effect percentages listed for Herceptin (trastuzumab) when used by itself.}

• Heart failure and other heart problems
• Infusion reactions
• Lung problems
• Harm to unborn baby
• Low blood counts when used with chemotherapy